Cargando…

Hospitalization at the end of life in patients with multiple myeloma

BACKGROUND: Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where MM patients die and characterization of end-of-life hospitalizations is needed. METHODS: We utilized the National Inpatient Samp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbasi, Saqib, Roller, John, Abdallah, Al-Ola, Shune, Leyla, McClune, Brian, Sborov, Douglas, Mohyuddin, Ghulam Rehman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011131/ https://www.ncbi.nlm.nih.gov/pubmed/33789626 http://dx.doi.org/10.1186/s12885-021-08079-x

Ejemplares similares

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
por: Balmaceda, Nicole, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
por: Steinbach, Mary, et al.
Publicado: (2022)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Financial toxicity in hematological malignancies: a systematic review
por: Ouchveridze, Evguenia, et al.
Publicado: (2022)

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
por: Griffin, Rosalie, et al.
Publicado: (2023)

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
por: Ahmed, Nausheen, et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population
por: Barth, Dylan, et al.
Publicado: (2022)

Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

A Rare Presentation of a Rare Disease: Pulmonary Lymphomatoid Granulomatosis
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2012)

Differential loss of components of traditional ecological knowledge following a primate extinction event
por: Turvey, Samuel T., et al.
Publicado: (2018)

A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection—A Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination
por: Abdallah, Al-Ola, et al.
Publicado: (2021)

Applying the Principles of Bloom’s Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2019)

Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias?
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
por: Reynolds, Gemma, et al.
Publicado: (2023)

P1518: INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Reynolds, Gemma, et al.
Publicado: (2023)

Engineering orthogonal signaling pathways reveals the sparse occupancy of sequence space
por: McClune, Conor J., et al.
Publicado: (2019)

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study
por: Bennink, Christine, et al.
Publicado: (2023)

BEAM Conditioning Is Well Tolerated and Yields Similar Survival in Obese and Non-Obese Patients with Lymphoma: No Requirement for Weight-Based Dose Modifications
por: Fair, Christina, et al.
Publicado: (2017)

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
por: Lonial, Sagar, et al.
Publicado: (2021)

Reducing Resident Physician Workload to Improve Well Being
por: Al-kofahi, Mejalli, et al.
Publicado: (2019)

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
por: Ferreri, Christopher J., et al.
Publicado: (2023)

Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
por: Masood, Ashiq, et al.
Publicado: (2021)

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
por: Hegerova, Livia, et al.
Publicado: (2017)

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
por: Hoering, Antje, et al.
Publicado: (2017)

Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
por: Atrash, Shebli, et al.
Publicado: (2023)

Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
por: Liu, Enze, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eh67gqdm6d0kribvsuloekepga